All News
Proposed Cancer Screening for Inflammatory Myositis Patients
Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue.
Read Article
Good news for patients who require short interruptions in biologic therapy!
Majority of axSpA patients (82%) who restarted ixekizumab after withdrawing, achieved low disease activity and 68% eventually had inactive disease.
#Abs0427 @RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
Hajj-Ali @RulaHajjAliMD et al. Worse PROs neuro AAV. Lower SF-36 Physical Functioning, Limitations in Physical role, Bodily Pain, and PCS. Higher PROMIS pain, lower PROMIS function @rheumnow #ACR22 Abstr#0437 https://t.co/ldC2VEZ0FV https://t.co/0pdjdSZQSS
Richard Conway RichardPAConway ( View Tweet)
Ab0192: UPA vs ADA vs PBO on RAPID3 in SELECT-PsA (bio-naive, P3 trial) #ACR22
UPA>ADA from wk 16-56. UPA and ADA>>PBO
Strongly associates with DAPSA or MDA/VLDA composite scores
@RheumNow https://t.co/ABY12ar7RS
Eric Dein ericdeinmd ( View Tweet)
Kakoullis et al. Steroid initiation within 1 week onset of GCA symptoms associated decreased relapse OR=0.216. @rheumnow #ACR22 Abstr#0469 https://t.co/sEW1V6NRpb https://t.co/4sAYZbmHX3
Richard Conway RichardPAConway ( View Tweet)
Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz
Dr. Rachel Tate uptoTate ( View Tweet)
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
Richard Conway RichardPAConway ( View Tweet)
Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws
Richard Conway RichardPAConway ( View Tweet)
Bui et al. Screening for ANCA in ILD. Present in 9.8% . 65.4% of these had AAV. No difference in pulmonary outcomes. More steroids, immunosuppressives, hospitalisations. @rheumnow #ACR22 Abstr#0438 https://t.co/RGdnDWSpNF https://t.co/xYeCUoTqqy
Richard Conway RichardPAConway ( View Tweet)
Endothelin-1, pro-inflammatory protein involved in multiple vascular and fibrosing abnormalities, may be a biomarker for differentiating between IPF and IIM-ILD or SSc-ILD. I'm always interested in potential biomarkers for clinic! Abs 0123 #ACR22 @RheumNow https://t.co/I69X4V0Zoa
Dr. Rachel Tate uptoTate ( View Tweet)
BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure.
@RheumNow ABST0267 #ACR22 #ACRBest
https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh
Julian Segan JulianSegan ( View Tweet)
#abst037 #acr22 @rheumnow REGISPONSER & RESPONDIA study of 231 pts w/late- vs early-onset PsA: late-onset> often male , ⬆️structural damage, ⬆️ FASFI, ⬆️ UE arthritis. Sacroiliitis& enthesitis ⬇️ frequent in late-onset. No effect on quality of life, dis activity & Rx choice https://t.co/IPRc1r2sxZ
Olga Petryna DrPetryna ( View Tweet)
How do we decide which RA patients are best for #telehealth?
Abstract #1291, Ignite session
🖥@DavidLeverenz et. al created a predictive model to answer this question
🖥Patient age, diagnosis, medications, and RAPID3 score impacted the model
@RheumNow #ACR22 https://t.co/JztTbQ4zfZ
Catherine Sims, MD DrCassySims ( View Tweet)
Leung et al @drceowen @drdavidliew persistence of fatigue, sleep and mood disorders in treated PMR patients in clinical remission. higher PSQI (lower quality sleep), higher BRAF (fatigue), higher HAD (depression, anxiety) @rheumnow #ACR22 Abstr#0204 https://t.co/zoeBNO6vVD https://t.co/TGC57kj6of
Richard Conway RichardPAConway ( View Tweet)
RTX vs CYCLO for CTD ILD
🌟RECITAL trial🌟
🫁Best ⬆️ in lung fn seen in IIM + MCTD assoc ILD for both agents
🫁SSc-ILD- lung function stabilisation only (no ⬆️)
👉 In SSc RTX improved skin thickness (mRss 24wks)
⬇️ a/e RTX
#ACR22 @RheumNow
Abst#0003 #plenary https://t.co/XdaaSFfxSP
Patricia Harkins DrTrishHarkins ( View Tweet)
Question is: does early stage PNL protect vs vascular remodelling in GCA? What about TCZ?
Salvarini group:
18 new GCA pts
GUSTO Rx (TCZ +IVMPx3, no ongoing PNL)
PET/CT: 0, 24, 52w
inflamm controlled but aortic diltation
plausible concerns reinforced!
ABST0480 #ACR22 @RheumNow https://t.co/Wnw4oxaZn7
David Liew drdavidliew ( View Tweet)
RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6
Janet Pope Janetbirdope ( View Tweet)
I implemented a Fast Track GCA clinic at my hospital (>60 encounters now!)
I have have begun to think the main benefit is ACCESS
Ultrasound is great and I do them, but I recommend starting one REGARDLESS of whether or not you do ultrasound
#ACR22 @RheumNow #0463 https://t.co/4uuotmNnoi
Mike Putman EBRheum ( View Tweet)
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow https://t.co/NhJKXRdw7q
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#acr22 #abst0003 @RheumNow RECITAL: RTX vs CYC for CTD related ILD:comparable in MCTD, CYC better for myositis related ILD. Both stabilize but not improve FVC in SSc ILD. In SSc RTX but not CYC improved skin thickness by mRss at 24 wks. better safety of RTX vs CYC #acrbest https://t.co/6Hry5hy1SS
Olga Petryna DrPetryna ( View Tweet)